ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

R-CHOP versus R-bendamustine in FL

Автор: VJHemOnc – Video Journal of Hematology & HemOnc

Загружено: 2021-12-16

Просмотров: 439

Описание: Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, describes the effect of immuno-chemotherapy in the Phase III FOLL12 trial (EudraCT: 2012-003170-60), which assessed patients receiving R-CHOP or rituximab with bendamustine, followed by rituximab maintenance or a response adapted post induction management in patients with follicular lymphoma. Administration of R-CHOP or rituximab with bendamustine was left to the doctor’s discretion and both regimes were found to yield similar responses and progression-free survival in patients. Maintenance rituximab was additionally found to be superior to the response-based post-induction approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
R-CHOP versus R-bendamustine in FL

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

Looking forward to ASH 2021: key updates in DLBCL

Looking forward to ASH 2021: key updates in DLBCL

Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations

Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations

CML Hilights of ASH 2025 - Biological Overview Including Q&A Session

CML Hilights of ASH 2025 - Biological Overview Including Q&A Session

2026 — Вебинар — ECD: взгляд нефролога — Мо Атта

2026 — Вебинар — ECD: взгляд нефролога — Мо Атта

MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays

MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays

Делайте ЭТИ 7 упражнений и вы удивитесь результату! Тело становится крепким как в 20 лет!

Делайте ЭТИ 7 упражнений и вы удивитесь результату! Тело становится крепким как в 20 лет!

The Cost of High-Masking AuDHD: Navigating Burnout After Success

The Cost of High-Masking AuDHD: Navigating Burnout After Success

De-escalated PTCy plus ruxolitinib for GvHD prophylaxis in older patients undergoing RIC alloSCT

De-escalated PTCy plus ruxolitinib for GvHD prophylaxis in older patients undergoing RIC alloSCT

Can JAK2V617F VAF variations help predict clinical and survival outcomes?

Can JAK2V617F VAF variations help predict clinical and survival outcomes?

Manali Kamdar, MD,  on “Expanding access to CAR T-cell therapy outside academic centers.”

Manali Kamdar, MD, on “Expanding access to CAR T-cell therapy outside academic centers.”

Significant advances made in Ph+ ALL: TKIs, immunotherapy & more

Significant advances made in Ph+ ALL: TKIs, immunotherapy & more

FOLL12: MRD monitoring in patients with FL

FOLL12: MRD monitoring in patients with FL

ASH 2025 Expert Insights: A New BTK Degrader Shows Promise in R/R CLL

ASH 2025 Expert Insights: A New BTK Degrader Shows Promise in R/R CLL

The Injury That Almost Ended Sidney Crosby’s Career: What Doctors Missed

The Injury That Almost Ended Sidney Crosby’s Career: What Doctors Missed

MSCs: From clinical trials to clinical practice

MSCs: From clinical trials to clinical practice

Вся правда о БАДах. Что нужно знать каждому?

Вся правда о БАДах. Что нужно знать каждому?

CML Hilights of ASH 2025 - Clinical Overview

CML Hilights of ASH 2025 - Clinical Overview

Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN?

Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN?

Challenges associated with Ph+ ALL: identifying high-risk patients & novel therapies being explored

Challenges associated with Ph+ ALL: identifying high-risk patients & novel therapies being explored

New Way to Manage Polycythemia Vera

New Way to Manage Polycythemia Vera

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]